Adenoviruses are important causes of infections in both immunocompetent and immunocompromised individuals. With immunocompromised patients, viral disease arising from adenovirus is associated with a high degree of morbidity and mortality.1
Quantitative detection of human adenovirus with polymerase chain reaction (PCR) can be used as a predictor tool in the decision to initiate or assess response to therapy in symptomatic transplant patients.2
The UC-TIB-AdV test is a real-time PCR test for the detection and quantification of human adenovirus in EDTA plasma to aid in the diagnosis of AdV infections and monitoring of AdV DNA levels. The test has been designed to work in conjunction with the cobas® omni utility channel for use on the cobas® 6800/8800 Systems available in countries accepting CE-IVD.
Results are traceable to the World Health Organization international standard for Adenovirus (NIBSC code: 16/324) reporting in IU/mL for improved result harmonisation across different laboratories and hospital institutions.
Specifically designed and optimized for use on the cobas® 6800/8800 Systems, enabling menu testing consolidation and sample to result automation.
The test minimizes variability and complexity in testing, offering an alternative to lab-developed tests (LDTs), reducing workload and alleviating risk of error for laboratories.
Parameter | Performance |
Conserved assay target | Hexon region |
Sample type | EDTA plasma |
Minimum amount of sample required | 350 uL |
Sample processing volume | 200 μL |
Analytical sensitivity | 39.5 IU/mL |
Linear range | 1E+02 IU/mL to 1E+08 IU/mL |
Specificity | 100% |
Species groups detected | ADV (A to G) |
Overall Precision | SD 0.06 - 0.16 log10 |
Kit stability | 90 days with 35 re-uses* |
References
Florescu et al. Adenovirus in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. The J of Clinical and Translational Research. 2019. https://doi.org/10.1111/ctr.13527
Lion T. Adenovirus infections in immunocompetent and immunocompromised patients. Clin Microbiol Rev. 2014;27(3):441–462. doi:10.1128/CMR.00116-13